- Trials with a EudraCT protocol (70)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (152)
70 result(s) found for: Osteosarcoma.
Displaying page 3 of 4.
EudraCT Number: 2020-002366-13 | Sponsor Protocol Number: IB2020-02 | Start Date*: 2021-12-20 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas | |||||||||||||
Medical condition: Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001709-24 | Sponsor Protocol Number: FIICGDTIC | Start Date*: 2005-08-24 |
Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS) | ||
Full Title: Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adulto | ||
Medical condition: Sarcomas de partes blandas | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004465-32 | Sponsor Protocol Number: 2011/386 | Start Date*: 2011-12-12 | |||||||||||
Sponsor Name:Dept. of Cardiothoracic & Vascular Surgery, Aarhus University Hospital, Skejby | |||||||||||||
Full Title: Can post-operative treatment with parathyroid hormone enhance bone healing and quality of newly formed bone after sternotomy in cardiac surgery patients? | |||||||||||||
Medical condition: Sternotomy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001272-39 | Sponsor Protocol Number: GP/C/02/SAR | Start Date*: 2005-10-21 |
Sponsor Name:GP-PHARM, S.A. | ||
Full Title: Estudio multicéntrico, prospectivo, abierto, no controlado en pacientes con edad igual o superior a 65 años para evaluar la eficacia y seguridad de Doxorubicina liposomal (Doxorubicina GP-Pharm) en... | ||
Medical condition: Sarcoma de partes blandas | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014889-26 | Sponsor Protocol Number: EORTC 62091 | Start Date*: 2011-12-15 | |||||||||||
Sponsor Name:EORTC (European Organisation for Research and Treatment of Cancer) | |||||||||||||
Full Title: TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Ti... | |||||||||||||
Medical condition: Histologically proven advanced and/or metastatic malignant soft tissue sarcoma intermediate/high grade, excluding the following tumor types : Well-differentiated liposarcoma Embryonal rhabdomyo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) HU (Completed) DK (Completed) AT (Completed) NL (Completed) SK (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002359-39 | Sponsor Protocol Number: 213406 | Start Date*: 2020-09-18 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS | ||||||||||||||||||
Medical condition: Recurrent or refractory solid tumour | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002231-92 | Sponsor Protocol Number: AP23573-04-202 | Start Date*: Information not available in EudraCT |
Sponsor Name:ARIAD Pharmaceuticals, Inc. | ||
Full Title: A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced Sarcoma | ||
Medical condition: Metastatic and/or unresectable soft tissue or bone sarcoma (excluding GIST). | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004045-16 | Sponsor Protocol Number: ET18-272 | Start Date*: 2019-03-14 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bo... | ||
Medical condition: Patients with bone sarcomas other than Ewing sarcoma or chondrosarcoma or chordoma, who have no residual disease after neoadjuvant chemotherapy, surgery and/or adjuvant chemotherapy. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005219-36 | Sponsor Protocol Number: B9E-MC-S378 | Start Date*: 2006-03-06 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors | ||
Medical condition: Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001152-39 | Sponsor Protocol Number: SSG XX | Start Date*: 2024-05-21 |
Sponsor Name:Scandinavian Sarcoma Group | ||
Full Title: SSGXX A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall | ||
Medical condition: SSG XX is a phase II trial for high-risk soft tissue sarcoma(STS) of the extremities and trunk wall. Prognostic markers are used to identify high-risk tumors. SSG XX will evaluate chemo-and radioth... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004040-10 | Sponsor Protocol Number: GEIS-52 | Start Date*: 2017-02-24 |
Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS) | ||
Full Title: Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas | ||
Medical condition: Soft tissue sarcoma (undifferentiated pleomorphic sarcoma, synovial sarcoma, alveolar soft part sarcoma, clear cell sarcoma, angiosarcoma, epithelioid hemangiosarcoma, solitary fibrous tumor and ep... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005294-60 | Sponsor Protocol Number: CRAD001C24114 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis... | |||||||||||||
Medical condition: histological evidence of progressive or metastatic bone or soft tissue sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000522-58 | Sponsor Protocol Number: NPM001 | Start Date*: 2014-10-02 | |||||||||||
Sponsor Name:Klinikum der Universität München | |||||||||||||
Full Title: A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or ad... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003355-38 | Sponsor Protocol Number: D0816C00025 | Start Date*: 2019-12-05 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours | ||
Medical condition: Solid Tumours | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) AT (Prematurely Ended) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001141-41 | Sponsor Protocol Number: 08-C-0007 | Start Date*: 2012-09-18 | |||||||||||
Sponsor Name:National Cancer Institute NCI | |||||||||||||
Full Title: A PHASE I STUDY OF IPILIMUMAB (ANTI-CTLA-4) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH TREATMENT REFRACTORY CANCER | |||||||||||||
Medical condition: Sarcoma - Wilm's Tumor - Lymphoma - Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004039-19 | Sponsor Protocol Number: GEIS-51 | Start Date*: 2017-03-23 |
Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS) | ||
Full Title: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression. | ||
Medical condition: Patients with advanced soft tissue sarcomas and osteosarcomas | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004529-27 | Sponsor Protocol Number: 1216.18 | Start Date*: 2007-07-09 |
Sponsor Name:SCS Boehringer Ingelheim Comm.V | ||
Full Title: Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EO... | ||
Medical condition: patients with five different tumour entities will be included in the present trial: 1. squamous cell carinoma of the head and neck 2. breast cancer 3. ovarian cancer 4. soft tissue sarcoma 5. meanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000571-37 | Sponsor Protocol Number: ET21-030 | Start Date*: 2021-08-02 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: A multicenter, randomized, open-label phase II trial evaluating the association of Gadolinium-based nanoparticles (AGuIX®) with radiotherapy for the therapeutic management of patients with progress... | ||
Medical condition: Patients with metastatic renal cancer, melanoma or sarcoma, or with non-metastatic sarcoma (soft tissue, chondrosarcoma, osteosarcoma…), and with a progressive / recurrent inoperable musculoskeleta... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004486-17 | Sponsor Protocol Number: A4021020 | Start Date*: 2008-08-26 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING’S SARCOMA FAMILY OF TUMORS | |||||||||||||
Medical condition: Ewing's sarcoma family tumours | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Not Authorised) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004441-33 | Sponsor Protocol Number: MK-7902-013(E7080-G000-231) | Start Date*: 2020-07-10 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies | |||||||||||||
Medical condition: Relapsed/Refractory pediatric solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) SE (Completed) HU (Completed) Outside EU/EEA BE (Completed) IT (Trial now transitioned) ES (Trial now transitioned) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
